Trevena Inc is a clinical stage biopharmaceutical company involved in the discovery and development of G-protein coupled receptors (GPCR) biased ligands. The Company's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena’s pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson’s disease.

Company Growth (employees)
Type
Public
HQ
King Of Prussia, US
Founded
2008
Size (employees)
72 (est)+36%
Trevena was founded in 2008 and is headquartered in King of Prussia, US

Trevena Office Locations

Trevena has an office in King of Prussia
King Of Prussia, US (HQ)
1018 West 8th Avenue

Trevena Data and Metrics

Trevena Financial Metrics

Trevena's revenue was reported to be $3.8 m in FY, 2016
USD

Net income (Q1, 2017)

(20.7 m)

Market capitalization (25-Jul-2017)

160.4 m

Cash (31-Mar-2017)

18.7 m
Trevena's current market capitalization is $160.4 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

6.3 m3.8 m

Revenue growth, %

(40%)

Net Income

(49.7 m)(50.5 m)(103 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(20.9 m)(36.4 m)(12.9 m)(24.4 m)(35.1 m)(17.8 m)(37 m)(66.9 m)(20.7 m)
USDFY, 2014FY, 2015FY, 2016

Cash

36.2 m46.8 m24.3 m

Accounts Receivable

4.1 m

Inventories

669.2 k1.9 m1.8 m

Current Assets

107.6 m174.5 m112.4 m

PP&E

553.3 k696.3 k1.1 m

Total Assets

108.3 m175.4 m114.7 m

Accounts Payable

4.3 m6.7 m8.7 m

Current Liabilities

7 m13.6 m22 m

Total Liabilities

36.1 m

Additional Paid-in Capital

231.2 m325.8 m364.1 m

Retained Earnings

(132 m)(182.5 m)(285.6 m)

Total Equity

99.2 m143.1 m78.6 m

Financial Leverage

1.1 x1.2 x1.5 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

81.6 m72.2 m29.1 m43.7 m39 m34.5 m36.8 m25.2 m18.7 m

Current Assets

84.2 m73.1 m102.5 m107.3 m170 m166 m147.6 m121.3 m100.8 m

PP&E

392.3 k594 k590.2 k609.3 k601.5 k823.5 k807.4 k745.3 k1.1 m

Total Assets

84.7 m74 m103.2 m108 m170.7 m166.9 m148.6 m122.1 m103.1 m

Accounts Payable

3.5 m3.9 m3.2 m4.1 m2.4 m4 m4.9 m6.9 m4.7 m

Current Liabilities

5.2 m7.5 m12.1 m13.2 m10.7 m9.5 m8.8 m15.1 m11 m

Additional Paid-in Capital

182.2 m182.9 m231.9 m249 m324.7 m338.8 m340.3 m342 m373.6 m

Retained Earnings

(103.1 m)(118.7 m)(144.9 m)(156.4 m)(167 m)(200.3 m)(219.5 m)(249.4 m)(306.3 m)

Total Equity

87.1 m92.7 m157.7 m138.6 m121 m92.7 m67.3 m

Financial Leverage

1.2 x1.2 x1.1 x1.2 x1.2 x1.3 x1.5 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(49.7 m)(50.5 m)(103 m)

Depreciation and Amortization

239.4 k207.9 k246 k

Accounts Receivable

(10.7 m)(17.5 m)

Inventories

(2.9 m)(2.8 m)

Accounts Payable

4.2 m2.8 m7.1 m

Cash From Operating Activities

(39.8 m)(40.1 m)(91.6 m)

Purchases of PP&E

(440.4 k)(361.2 k)(605 k)

Cash From Investing Activities

(71.2 m)(56.9 m)37.8 m

Cash From Financing Activities

109.2 m107.6 m32.3 m

Interest Paid

37.2 k154.6 k1.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(20.9 m)(36.4 m)(12.9 m)(24.4 m)(35.1 m)(17.8 m)(37 m)(66.9 m)(20.7 m)

Depreciation and Amortization

142.1 k184.9 k52.5 k104.5 k155.3 k57.5 k118.5 k180 k79 k

Accounts Payable

(2.4 m)(1.3 m)(1.9 m)(2.2 m)(1.1 m)620.8 k(9.9 m)

Cash From Operating Activities

(15.8 m)(26.7 m)(6 m)(16.3 m)(28.2 m)(20.6 m)(39.2 m)(63.9 m)(29.5 m)

Purchases of PP&E

(191.3 k)(421.5 k)(89.4 k)(160.6 k)(203.4 k)(175.3 k)(219.7 k)(228.9 k)(116 k)

Cash From Investing Activities

(191.3 k)(421.5 k)(1.2 m)7.3 m(60.1 m)(3.5 m)17.4 m30.4 m6.7 m

Cash From Financing Activities

59.6 m61.4 m178.8 k16.4 m91.2 m11.8 m11.9 m11.9 m17.1 m

Interest Paid

300.9 k601.8 k902.8 k304 k
Y, 2017

Financial Leverage

1.5 x

Trevena Market Value History

Trevena News and Updates

Trevena Company Life and Culture

You may also be interested in